News about Global Pharma

Lupin Expands US Footprint with New Corporate Offices in Bridgewater, New Jersey

Lupin has inaugurated its new corporate offices at 100 Somerset Corporate Blvd, Bridgewater, New Jersey, expanding its presence in the state where it already operates manufacturing and research facilities.

Global Pharma | 28/10/2025 | By Dineshwori |  327

Akums Expands Global Footprint with New Pharmaceutical Facility in Zambia

Akums Drugs & Pharmaceuticals has held the groundbreaking ceremony of its first overseas manufacturing facility in Zambia, marking a major milestone in its global expansion journey.

Global Pharma | 28/10/2025 | By Dineshwori |  284

Health Canada Grants Authorisation for Leqembi (Lecanemab)

BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.

Global Pharma | 28/10/2025 | By Dineshwori |  242

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

Global Pharma | 27/10/2025 | By Dineshwori |  328

Merck KGaA Reports Sustained Efficacy and Safety of OGSIVEO in Phase-III Desmoid Tumour Study

Merck KGaA has released long-term phase-III data showing that OGSIVEO treatment for up to four years continues to deliver durable tumour reductions, improved response rates, sustained symptom relief, and a consistent safety profile in patients with desmoid tumours.

Global Pharma | 27/10/2025 | By Dineshwori |  296

Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India

Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.

Global Pharma | 27/10/2025 | By Dineshwori |  586

Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia

Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.

Global Pharma | 24/10/2025 | By Dineshwori |  562

SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025

Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.

Global Pharma | 21/10/2025 | By Dineshwori |  403

FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes

Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.

Global Pharma | 21/10/2025 | By Dineshwori |  333

Aspire Pharma acquires Charlwood Pharma

Aspire Pharma, a UK-based specialty generics pharma business, has announced the acquisition of Charlwood Pharma Ltd — a privately-owned company specialising in the research and development of niche generic medicines. The deal marks the culmination of a successful multi-year collaboration between the two organisations.

Global Pharma | 21/10/2025 | By Dineshwori |  398